Coronavirus: LGBT People | Department of Health and Social Care | Written Answers To ask the Secretary of State for Health and Social Care, what assessment he has made of the health effects of the Covid-19 outbreak on (
Medical Treatments: Innovation | Department of Health and Social Care | Written Answers To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 February 2020 to Question 18743 on Medical Treatme
Health Services: Technology | Department of Health and Social Care | Written Answers To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence plans to publish
Orphan Drugs | Department of Health and Social Care | Written Answers To ask the Secretary of State for Health and Social Care, what assessment he made of the effect of the (a) introduction of the ultra-orph
Orphan Drugs | Department of Health and Social Care | Written Answers To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of establishing a new orpha
NHS: Drugs | Department of Health and Social Care | Written Answers To ask the Secretary of State for Health and Social Care, with reference to paragraph 3.21 of the 2019 voluntary scheme for branded medic
NHS: Drugs | Department of Health and Social Care | Written Answers To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of the NHS Commercial Frame
Medical Treatments: Innovation | Department of Health and Social Care | Written Answers To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 February 2020 to Question 18744 on Medical Treatme
Cancer: Drugs | Department of Health and Social Care | Written Answers To ask the Secretary of State for Health and Social Care, what Cancer Drugs Fund expenditure cap is for (a) 2019-20 and (b) 2020-21.
NHS: Drugs | Department of Health and Social Care | Written Answers To ask the Secretary of State for Health and Social Care, which medicinal products were made available on the NHS with a managed access a